Literature DB >> 22814776

Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.

Alaide Chieffo1, Emanuele Meliga, Azeem Latib, Seung-Jung Park, Yoshinobu Onuma, Piera Capranzano, Marco Valgimigli, Sanda Jegere, Raj R Makkar, Igor F Palacios, Young-Hak Kim, Pawel E Buszman, Tarun Chakravarty, Imad Sheiban, Roxana Mehran, Christoph Naber, Ronan Margey, Arvind Agnihotri, Sebastiano Marra, Davide Capodanno, Martin B Leon, Jeffrey W Moses, Jean Fajadet, Thierry Lefevre, Marie-Claude Morice, Andrejs Erglis, Corrado Tamburino, Ottavio Alfieri, Patrick W Serruys, Antonio Colombo.   

Abstract

OBJECTIVES: The aim of this study was to compare, in a large all-comers registry, major adverse cardiac and cerebrovascular events (MACCE) after percutaneous coronary intervention (PCI) with first-generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in unprotected left main coronary artery (ULMCA) stenosis.
BACKGROUND: Percutaneous coronary intervention with DES implantation in ULMCA has been shown to be a feasible and safe approach at midterm clinical follow-up.
METHODS: All consecutive patients with ULMCA stenosis treated by PCI with DES versus CABG were analyzed in this multinational registry. A propensity score analysis was performed to adjust for baseline differences in the overall cohort.
RESULTS: In total 2,775 patients were included: 1,874 were treated with PCI versus 901 with CABG. At 1,295 (interquartile range: 928 to 1,713) days, there were no differences, at the adjusted analysis, in the primary composite endpoint of death, cerebrovascular accidents, and myocardial infarction (MI) (adjusted hazard ratio [HR]: 1.11; 95% confidence interval [CI]: 0.85 to 1.42; p = 0.47), mortality (adjusted HR: 1.16; 95% CI: 0.87 to 1.55; p = 0.32), or composite endpoint of death and MI (adjusted HR: 1.25; 95% CI: 0.95 to 1.64; p = 0.11). An advantage of CABG over PCI was observed in the composite secondary endpoint of MACCE (adjusted HR: 1.64; 95% CI: 1.33 to 2.03; p < 0.0001), driven exclusively by the higher incidence of target vessel revascularization with PCI.
CONCLUSIONS: In our multinational all-comers registry, no difference was observed in the occurrence of death, cerebrovascular accidents, and MI between PCI and CABG. An advantage of CABG over PCI was observed in the incidence of MACCE, driven by the higher incidence of target vessel revascularization with PCI.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22814776     DOI: 10.1016/j.jcin.2012.03.022

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  26 in total

Review 1.  Appropriateness of percutaneous coronary intervention: a review.

Authors:  Matthew R Summers; Manesh R Patel
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

Review 2.  Almanac 2013: stable coronary artery disease.

Authors:  Shahed Islam; Adam Timmis
Journal:  Wien Klin Wochenschr       Date:  2013-12       Impact factor: 1.704

Review 3.  Stenting versus surgery for significant left main disease.

Authors:  Ralf E Harskamp; Duk-Woo Park
Journal:  Curr Cardiol Rep       Date:  2015       Impact factor: 2.931

4.  Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions.

Authors:  David van Klaveren; Yvonne Vergouwe; Vasim Farooq; Patrick W Serruys; Ewout W Steyerberg
Journal:  J Clin Epidemiol       Date:  2015-02-27       Impact factor: 6.437

5.  Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.

Authors:  K Ebina; M Hirao; J Hashimoto; H Matsuoka; T Iwahashi; R Chijimatsu; Y Etani; G Okamura; A Miyama; H Yoshikawa
Journal:  Osteoporos Int       Date:  2018-03-24       Impact factor: 4.507

6.  Unprotected Left Main Disease: Indications and Optimal Strategies for Percutaneous Intervention.

Authors:  Jun Li; Sandeep M Patel; Manish A Parikh; Sahil A Parikh
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-03

7.  Comparison of the Predictive Roles of Risk Scores of In-Hospital Major Adverse Cardiovascular Events in Patients with Non-ST Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.

Authors:  Erdal Aktürk; Lütfü Aşkın; Hakan Taşolar; Serdar Türkmen; Hakan Kaya
Journal:  Med Princ Pract       Date:  2018-04-19       Impact factor: 1.927

Review 8.  Optimal revascularization for complex coronary artery disease.

Authors:  Javaid Iqbal; Patrick W Serruys; David P Taggart
Journal:  Nat Rev Cardiol       Date:  2013-09-17       Impact factor: 32.419

9.  Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis.

Authors:  Daniele Giacoppo; Roisin Colleran; Salvatore Cassese; Antonio H Frangieh; Jens Wiebe; Michael Joner; Heribert Schunkert; Adnan Kastrati; Robert A Byrne
Journal:  JAMA Cardiol       Date:  2017-10-01       Impact factor: 14.676

10.  Percutaneous Coronary Intervention for Left Main Coronary Artery Disease - A Single Hospital Experience without On-Site Cardiac Surgery.

Authors:  Hsiao-Yang Cheng; Kuang-Te Wang; Wen-Hsiung Lin; Jui-Peng Tsai; Yung-Tzi Chen
Journal:  Acta Cardiol Sin       Date:  2015-07       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.